Valerion Therapeutics (United States)

Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion

M. Kathryn Brewer, Annette Uittenbogaard, Grant L. Austin et al. · Cell Metabolism · 2019 · 86 citations · Full text

Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease

Haiqing Yi, Tao Sun, Dustin Armstrong et al. · Journal of Molecular Medicine · 2017 · 28 citations · Full text

Cytoplasmic Glycogen, Pompe Disease, Autoimmune Disease +11

Central Nervous System Delivery and Biodistribution Analysis of an Antibody–Enzyme Fusion for the Treatment of Lafora Disease

Grant L. Austin, Zoe R. Simmons, Jack E. Klier et al. · Molecular Pharmaceutics · 2019 · 25 citations · Full text

Engineering, Immunology, Pathology +18

Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease

Priya S. Kishnani, Robin Lachmann, Tahseen Mozaffar et al. · Molecular Genetics and Metabolism · 2019 · 18 citations

Cytoplasmic Glycogen, Translational Medicine, Medicine +8

Biological-to-electronic interface with pores of ATP synthase subunit C in silicon nitride barrier

Julie E. M. McGeoch, Malcolm W. McGeoch, D. J. D. Carter et al. · Medical & Biological Engineering & Computing · 2000 · 17 citations

Engineering, Bioelectrochemistry, Medicine +8